90Y ibritumomab tiuxetan (Zevalin) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma).

Trial Profile

90Y ibritumomab tiuxetan (Zevalin) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2012

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Acronyms ZENO
  • Most Recent Events

    • 29 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top